Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Consensus Recommendation of “Hold” from Analysts

Repare Therapeutics Inc. (NASDAQ:RPTX) has been given an average recommendation of “Hold” by the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.50.

RPTX has been the topic of several analyst reports. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a report on Saturday, November 15th. TD Cowen lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their target price on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Finally, Cowen cut Repare Therapeutics to a “hold” rating in a research note on Monday.

Institutional Investors Weigh In On Repare Therapeutics

Several hedge funds have recently bought and sold shares of the company. Quinn Opportunity Partners LLC acquired a new position in shares of Repare Therapeutics in the 2nd quarter valued at $56,000. Affinity Asset Advisors LLC boosted its position in shares of Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after buying an additional 100,000 shares during the period. Acadian Asset Management LLC grew its stake in shares of Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after acquiring an additional 168,230 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Repare Therapeutics in the 3rd quarter valued at $115,000. Finally, Rangeley Capital LLC bought a new stake in Repare Therapeutics during the second quarter worth about $494,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Stock Up 0.5%

Repare Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $2.11. The stock had a trading volume of 1,178,199 shares, compared to its average volume of 1,054,180. The company has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.61. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.07. The company has a market cap of $90.71 million, a PE ratio of -1.25 and a beta of 1.06.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, analysts forecast that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.